

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

DR. WEICHEN ZHOU (Orcid ID : 0000-0003-4755-1072)

Article type : Method

Title

A standardized fold change (SFC) method for microarray differential expression analysis used to reveal genes involved in acute rejection in murine allograft models

Authors

Weichen Zhou^{1,3,†}, Yi Wang^{1,†}, Masayuki Fujino^{2,4}, Leming Shi¹, Li Jin¹, Xiao-Kang Li^{1,2,*}, Jiucun Wang^{1,*}

Addresses

¹State Key Laboratory of Genetic Engineering and Ministry of Education Key Laboratory of Contemporary Anthropology, Collaborative Innovation Center for Genetics and Development, School of Life Sciences and Institutes of Biomedical Sciences, Fudan University, Shanghai, China; ²Division of Transplantation Immunology, National Research Institute for Child Health and Development, Tokyo, Japan; ³Department of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, USA; ⁴AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan

[†]Weichen Zhou and Yi Wang contributed equally to this work.

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](https://doi.org/10.1186/1745-2758-12-343). Please cite this article as [doi: 10.1186/1745-2758-12-343](https://doi.org/10.1186/1745-2758-12-343)

This article is protected by copyright. All rights reserved

28 ***Corresponding authors**

29 Xiao-Kang Li, M.D., Ph.D., Division of Transplantation Immunology, National
30 Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku,
31 Tokyo, 157-8535 Japan.

32 Tel: +81-3-3416-0181; Fax: +81-3-3417-2864; E-mail: ri-k@ncchd.go.jp

33 Jiucun Wang, Ph.D., School of Life Sciences, Fudan University, 2005 Songhu Road,
34 Shanghai 200438, China.

35 Tel: +86-21-5163-0606; Fax: +86-21-5163-0607; E-mail: jcwang@fudan.edu.cn

36

37 **Running title**

38 SFC method for microarray analysis

39

40 **Abbreviations**

41 SFC: standardized fold change; Limma: linear models for microarray data; MAQC:
42 micro-array quality control; POD: days post operation; qRT-PCR: quantitative reverse
43 transcriptase-polymerase chain reaction; FPR: false positive rate; FNR: false negative
44 rate

45

46 **Keywords**

47 Murine transplantation model, microarray analysis, standardized fold change, gene
48 expressions

49

50 **Conflict of interest statement**

51 The authors have declared that no conflict of interest exists.

52 **Abstract**

53 Murine transplantation models are used extensively to research immunological
54 rejection and tolerance. Here, we studied on both murine heart and liver allograft
55 models using microarray technology. However, we had difficulties in identifying
56 genes related to acute rejections expressed in both heart and liver transplantation
57 models using two standard methodologies: Student's T-test and linear models for

58 microarray data (Limma). Here we describe a new method, standardized fold change
59 (SFC), for differential analysis of microarray data. We estimated the performance of
60 SFC, T-test and Limma by generating simulated microarray data 100 times. SFC
61 performed better than T-test and showed a higher efficiency than Limma in sensitivity
62 where a larger fold change of expression value exists. SFC had better reproducibility
63 than Limma and T-test in real experimental data from Micro-Array Quality Control
64 (MAQC) platform and expression data of mouse cardiac allograft. Eventually, a group
65 of significant overlapping genes was detected by SFC in the expression data of mouse
66 cardiac and hepatic allografts and further validated by the quantitative RT-PCR assay.
67 The group included genes for important reactions of transplantation rejection and
68 revealed functional changes of the immune system in both heart and liver of the
69 mouse model. We suggest that SFC can be utilized to stably and effectively detect the
70 differential gene expression and to explore microarray data in further studies.

71 **Introduction**

72 At the very stage of organ failure, the organ transplantation is the life-saving
73 medical procedure, though still having some problems, e.g., transplant rejection,
74 reception of life-long immunosuppressive drugs. Transplantation models without
75 immunosuppression are important and the mechanisms of rejection and tolerance in
76 these models are highly required to be disclosed.

77 The microarray is a well-established and widely used technology, providing a
78 picture of gene expression or RNA profiling in different tissues [1]. To identify the
79 differential expressions, Student's *T-test* and linear models for microarray data (*Limma*)
80 are two popular choices [2-4]. *T-test* utilizes information of all the samples (or
81 standard deviation) in one microarray probe and conducted independently among
82 different probes [4]; while *Limma* uses the empirical Bayes approach to shrinkage of
83 the estimated sample variances towards a pooled estimate. The information (means
84 and standard deviations) from all probes in a replicate set of experiments are
85 combined and used at one probe level to detect differential expressions in *Limma* [2].

86 In the present study, we estimated murine heart and liver allograft models and
87 conducted microarray technology to reveal the significant genes that related to

88 transplant rejection. By using *T-test* and *Limma*, no significant intersecting genes were
89 obtained in the models of murine heart and liver allografts. Therefore, we developed a
90 new method named Standardized Fold Change (*SFC*) to detect differential
91 expressions by borrowing information from neighbors of one probe with an adjustable
92 bin size. To compare *SFC* with *T-test* and *Limma*, we generated a simulated data set to
93 estimate the performance and conducted the real experimental datasets from
94 Micro-Array Quality Control (MAQC) platform and the transplantation model to
95 estimate the reproducibility. We concluded that *SFC* can be applied as a new and
96 effective approach for differential expression detection and contribute more reliable
97 results in the microarray studies. Eventually, we called a set of significant genes from
98 expression data of murine heart and liver allograft model by *SFC* and validated them
99 by qRT-PCR. Gene expression changes reveal functional reactions and pathway
100 activities in the early stage of allograft in both heart and liver.

101

102 **Results**

103 *The SFC method*

104 We observed the distribution of the mean value and variance of one probe signal
105 is non-linear (**Supplementary Figure 1**). The information of neighboring probes can
106 usually be borrowed to improve the statistical power [2]. *SFC* was introduced to
107 estimate variance for each probe: rather than obtaining from all samples; it takes
108 information from neighbors of that probe with an adjustable bin size b . As we set up
109 the default value of b as 1000, the variances of cases and controls in one probe can be
110 obtained by calculating the median of those probes, separately. Eventually, following
111 by the Formula (1), we can obtain the statistic *SFC* for every probe, and p -value can
112 be further estimated based on these.

113

114 *SFC had a better sensitivity and specificity based on simulation data*

115 We investigated the false positive rate (FPR) and the false negative rate (FNR) of
116 these three methods under the null hypothesis and alternative hypothesis. As indicated
117 in Formula (2), signals of the null hypothesis were generated by a simple formula $y=x$

118 with a Gaussian noise added. The basic formulas are adjustable with the parameters k .
119 The signals of alternative hypothesis were described by Formula (3), with variable
120 values of θ and the portion of real positive calls. We calculated the FPR and FNR for
121 every different θ and portion of real positive calls with a 0.05 significant threshold
122 and 100-time simulation (**Table 1**).

123 Under the null hypothesis, the rates of three methods are all near the significant
124 threshold between 5% and 6% (**Figure 1A**). Under the alternative hypothesis, *SFC*
125 had a better performance of FPR than the other two methods generally (**Figure 1B**).
126 With an increasing θ and portion of real positive calls, the FPR of *SFC* showed a
127 decreasing bias, whereas *Limma* and *T-test* showed a positive bias with these
128 parameters (**Table. 1**). To the FNR, as the θ and portion of real positive calls increase,
129 *Limma* showed a faster decline than *T-test*, while *SFC* had a lower FNR than *Limma*
130 and performed better with larger θ and portion of real positive calls. Interestingly,
131 *SFC* shows a relatively small number of calls (from 4.9% to 10.5%, **Table. 1**), while
132 *Limma* and *T-test* calls a larger set in this situation. To sum, comparing with *Limma*
133 and *T-test* at the significant threshold of 0.05, *SFC* had a better sensitivity and
134 specificity, especially with a larger value of differential expression fold change ($\theta =$
135 50%).

136
137 *Reproducibility of SFC is better than Limma and T-test based on MAQC and mouse*
138 *transplantation data*

139 Reproducibility is an indispensable estimator for the experiments and algorithms
140 [5, 6]. We choose both MAQC dataset and mouse cardiac transplantation data to
141 assess the reproducibility of *SFC*, *Limma* and *T-test*.

142 We calculated the reproducibility of top 100 and top 1000 genes for MAQC by
143 using the three methods. For the inter-platform, heat-map shows that *SFC* performed a
144 better reproducibility than *Limma* and *T-test* among six platforms when detecting both
145 top 100 and top 1000; while for intra-platform reproducibility, all three methods did
146 not perform well in detecting either top 100 or 1000 significant genes (**Figure 2A&B**).
147 Same operations were conducted in the mouse cardiac transplantation data, where

148 *SFC* also showed a better performance than the others (**Figure 2C**). Therefore,
149 according to better performances of reproducibility in both MAQC data and mouse
150 transplantation data, *SFC* is more stable than *Limma* or *T-test*.

151
152 *Intersected significances from mouse transplantation data were found by SFC and*
153 *validated by qRT-PCR*

154 We further utilized the three methods to analyze the mouse organ transplantation
155 data and validated the results. After experimental process generating CEL files from
156 mouse tissues, we conducted these methods on the expression data of POD5 of
157 cardiac transplantation and the POD5 and POD8 of hepatic transplantation.

158 According to *SFC*, one hundred and seventy-eight significant genes were
159 differentially expressed in the cardiac allografts compared with isografts, including
160 158 over-expressed genes and 20 under-expressed genes (**Figure 3**). There were also
161 362 genes (263 over-expression and 99 under-expression) have significantly different
162 expressions in the hepatic POD5 allografts compared with isografts, and 389 genes
163 (258 over-expression and 131 under-expression) have significantly different
164 expressions in the hepatic POD8 allografts compared with isografts, respectively.
165 Based on these, an intersection of these three groups including 52 important genes
166 was obtained, in which they are all over-expressed for cardiac transplantation and 51
167 over-expressed and one under-expressed for hepatic transplantation (**Figure 3**). At the
168 same time, the calling sets of significant genes underlying *Limma* and *T-test*
169 (**Supplementary Figure 4A&B**) showed no intersected ones.

170 We further performed quantitative RT-PCR for the calls derived from *SFC* to
171 validate the fold changes of the mRNA expressions. Nineteen mRNAs, which were
172 up-regulated in both of cardiac and hepatic allografts compared with isografts, were
173 randomly selected (**Table 2 & Supplementary Table 3**). Being consistent with the
174 results of microarray, a significantly higher amount of mRNA expression was detected
175 in allografts versus isografts in cardiac (**Figure 4A**) and hepatic (**Figure 4B**)
176 allografts.

177

178 **Discussion**

179 Microarray is widely used and accepted as a stable, well established and less
180 costing technology to investigate gene expression data [1, 7-9]. In this study based on
181 the microarray data, we established a novel method *SFC* to detect differential
182 expressions and compared it with *T-test* and *Limma*. According to the Formula (1),
183 the parameter b can be adjusted to control the nearby number of probes, which
184 contribute the variant of the central probe. We set 1000 as default, and users can
185 customize its value based on a different size of microarray probes. For the simulation
186 data, the parameter configurations (θ and k) of the null hypothesis and alternative
187 hypothesis also can be adjusted (Formula 2&3) [10]. Moreover, we calculated the
188 FPR and FNR based on different significant levels (p -value = 0.01 and 0.001) for
189 different values of θ and k . With a more stringent significant level (from 0.05 to
190 0.001), the FPRs were decreasing while the FN rates were increasing, which was
191 observed by all three methods (**Figure 1, Supplementary Figure 2&3, Table 1, and**
192 **Supplementary Table 1&2**). Notably, when p -value equals to 0.001, *T-test*
193 performed a high FPR (48%, $\theta = 50\%$, and true positive gene percent = 10%) and
194 *Limma* performed with a high FNR (sometimes more than 90%). These suggested the
195 *T-test* choose to give more positive hits with high FPR, while *Limma* will report fewer
196 hits to reduce the FPR but miss some TP ones. Importantly, *SFC* can make a good
197 balance of FPR and FNR, and perform well both in FPR and FNR with stringent
198 significant level.

199 Statistical correction (e.g. Bonferroni correction) is often introduced for multiple
200 comparisons to adjust p -value and control the false discovery rate [11]. We also
201 analyzed the mice transplantation data by the other two methods (*Limma* and *T-test*)
202 on the different significant levels (p -value = 0.05, 0.001, and 0.05 with Bonferroni
203 correction). *Limma* and *T-test* had a huge number of positive hits when the p -value is
204 0.05 in three phases (**Supplementary Figure 5&6**). When p -value is 0.001, the
205 positive hits by *Limma* and *T-test* decreased a lot while by *SFC* the number stayed
206 respectively stable. When p -value was stringent to 0.05 with Bonferroni correction
207 (**Figure 3 & Supplementary Figure 4**), *SFC* still reported 52 significances

208 overlapping with three phases, but *Limma* and *T-test* showed no overlapping
209 significance. The results of *T-test* showed no sharing significance with *SFC*.
210 Intriguingly, in 67 significances of cardiac POD5 reported by *Limma*
211 (**Supplementary Figure 4**), thirty genes showed in the cardiac POD5 result of *SFC*,
212 and 16 showed in the 52 significances. Besides, for hepatic POD5 and POD8 by
213 *Limma*, 4 out of 7 (POD5) and 19 out of 36 (POD8) were observed in the
214 corresponding results of *SFC*, and 2 out of 5 (overlapping in POD5 and POD8) appear
215 in the 52 genes of *SFC*. As 19 in 52 genes from *SFC* were randomly selected and all
216 passed the validation of qRT-PCR, these results indicated that *SFC* had a more stable
217 result than *T-test* and *Limma*.

218 We, therefore, investigated the functions of these 52 genes (**Supplementary**
219 **Table 4**), revealing the most significant pathways were graft-versus-host disease
220 (mmu05332) and allograft rejection (mmu05330). Moreover, immune system
221 response (e.g. mmu04612, mmu04660, GO: 0006955) and positive regulation (e.g.
222 GO: 0050863, GO: 0051249, GO: 0050870) were also activated. All these enrichment
223 analyses indicated a reaction of transplantation rejection in vivo and functional
224 changes of immune system both in cardiac and hepatic level after five days of
225 allografts [12-14].

226 In conclusion, based on the quality control experimental data and simulated data,
227 *SFC* performed some better than *Limma* and much better than *T-test* by using the
228 nearby information of one probe in pooled probes. We utilized *SFC* into the real data
229 of mouse transplantation models, and it reported a more stable and convincing set
230 with 52 significant genes, revealing the insights of pathway and gene expression
231 changes after both cardiac and hepatic allografts. Nineteen genes were further
232 randomly picked up and validated by qRT-PCR. We suggested *SFC* is a new and
233 effective approach, which can detect differential expressions and help to find more
234 reliable information in microarray studies.

235

236 **Materials and Methods**

237 *Animal*

This article is protected by copyright. All rights reserved

238 Male B10.BR (BR, H-2k), B10.D2 (D2, H-2d), C57BL/ 10 (B10, H-2b), and
239 CBA (H-2k) mice (weighing 25-30 g) were purchased from the Shizuoka Laboratory
240 Animal Center (Shizuoka, Japan) and housed and cared for in agreement with the
241 guidelines of the Institutional Animal Care and Use Committee and the National
242 Research Institute for Child Health and Development guidelines on laboratory animal
243 welfare. The Committee on the Care and Use of Laboratory Animals at the National
244 Research Institute accepted the experimental protocol for Child Health and
245 Development (Permission Number: 2002-003). All surgical procedures were
246 conducted by anesthetization with isoflurane/oxygen, and all attempts were carried
247 out to minimize suffering.

248

249 *Transplantation and RNA extraction*

250 The cardiac transplantation was performed on the sex-matched B10 donor to the
251 CBA recipient by microsurgical techniques. Intra-abdominal vascularized heterotopic
252 mouse cardiac transplantation was performed [15]. The cardiac graft survival was
253 determined using daily palpation of the recipient's abdomen. Three case samples on
254 the fifth day were obtained. BR mice were used as donors and D2 mice were used as
255 recipients in the orthotopic hepatic transplantation. We performed transplantation
256 surgery on the mice [12]. For orthotopic liver transplantation, BR mice were used as
257 donors and D2 mice were used as recipients. We subsequently transplanted the
258 hepatics into the recipient mice using the cuff technique [12]. Grafts were harvested at
259 5 days post operation (POD5) or POD8 after transplantation and were submerged in
260 RNeasy[®] stabilization solution (Life Technologies, Carlsbad, CA) for freezing.
261 Total RNA was extracted from frozen tissue samples using ISOGEN (NipponGene,
262 Tokyo, Japan). We also designed control groups of three normal cardiac tissues and
263 three hepatic tissues.

264

265 *Standardized fold change method*

266 The probe signals from microarray data were firstly transformed by Ln and then
267 manipulated with quantitative normalization. To assess the differential expressions

268 among cases and controls, the statistics *SFC* is defined as:

$$\begin{aligned}
 269 \quad SFC_i &= \frac{T - C}{STDEV(T - C)} = \frac{T_i - C_i}{\sqrt{Var(T - C)}} \\
 &= \frac{Median(t_1, t_2, \dots, t_i) - Median(c_1, c_2, \dots, c_i)}{\sqrt{Median((T_{i-b/2} - C_{i-b/2})^2, \dots, (T_i - C_i)^2, \dots, (T_{i+b/2} - C_{i+b/2})^2) / 0.455}}
 \end{aligned} \tag{1}$$

270 For the variance of each probe, we ranked all probes by the mean values of signals
 271 from all samples and then took the median value of its *b* nearest neighbors as the
 272 variance, where the default bin size of *b* here is 1000. The *SFC* software now
 273 implements this algorithm in Linux system at <https://github.com/WeichenZhou/SFC>.

274

275 *Simulation data study*

276 We generated the simulated data from simple formulas with the Gaussian noise
 277 (mean = 0, variance = 1) as a default distribution for gene expression data [16]. The
 278 control and case samples in the null hypothesis are shown as follows:

$$\begin{aligned}
 279 \quad H_0 \text{ control} &: y_0 = x_0 + \mathcal{N}(0,1) (\sqrt{kx_0} + 1) \\
 280 \quad H_0 \text{ case} &: y_0' = (1 + \theta_0)x_0' + \mathcal{N}(0,1) (\sqrt{kx_0'} + 1)
 \end{aligned} \tag{2}$$

281 The θ represented the differential expression underlying cases versus controls and we
 282 defined θ_0 is 0% and *k* is 1. The control and case samples in the alternative hypothesis
 283 are shown as follows:

$$\begin{aligned}
 284 \quad H_1 \text{ control} &: y_1 = x_1 + \mathcal{N}(0,1) (\sqrt{kx_1} + 1) \\
 285 \quad H_1 \text{ case} &: y_1' = (1 + \theta_1)x_1' + \mathcal{N}(0,1) (\sqrt{kx_1'} + 1)
 \end{aligned} \tag{3}$$

286 We defined θ_1 as 10%, 25% and 50%, respectively. The size of real positive calls
 287 consists 1%, 5%, 10% of the whole simulated data, respectively. Following these, a
 288 100-time simulation was conducted to assess FPR and FNR.

289

290 *MAQC data and the reproducibility analysis*

291 MAQC data was conducted by the US Food and Drug Administration (FDA) to
 292 develop standards and quality control metrics, which involved six Centers (ABI, AFX,
 293 AGI, GEH, ILM, and NCI) major providers of microarray platforms and RNA

294 samples [1, 7]. The reproducibility of top 100 significant genes and 1000 significant
295 genes were estimated in the inter- and intra-platform by the three statistical methods
296 and the heat maps were drawn with the matrix of each batch. For the expression data
297 from mouse transplant model, we picked up two out of three cases and controls to
298 build one batch and made a 9x9 matrix heat map to estimate the reproducibility. The
299 significant level of mice microarray data was 0.05.

300

301 *Application on mouse transplantation data*

302 We detected the gene differential expressions between cases and controls in three
303 phases: POD5 of cardiac transplantation, POD5 of hepatic transplantation and POD8
304 of hepatic transplantation. All *p*-values from expression data are adjusted by the
305 Bonferroni correction. After getting all significant probes from *SFC*, we converted
306 these probe level significance to gene level using annotation file. The Venn diagrams
307 showed the significant genes with differential expression. Pathway and GO
308 enrichment analyses were performed by using the Database for Annotation,
309 Visualization and Integrated Discovery (DAVID) database
310 (<http://david.abcc.ncifcrf.gov/>) with the Bonferroni correction adjusted *p*-values less
311 than 0.05 [17]. Mouse transplantation data have been deposited in NCBI's Gene
312 Expression Omnibus [18] and are accessible through GEO Series accession number
313 GSE89340
314 ([https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=qrmliwycxlovtuf&acc=GSE](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=qrmliwycxlovtuf&acc=GSE89340)
315 [89340](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=qrmliwycxlovtuf&acc=GSE89340)). All data were conducted by quantile normalization before processed by
316 different methods. *Limma* can be found as the R package *Limma* [2, 3] and the heat
317 maps were conducted by *gplots*. All R packages can be downloaded from
318 Bioconductor (www.bioconductor.org).

319

320 *Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR)*

321 The RNA was reverse-transcribed to cDNA using a PrimeScript® RT Reagent Kit
322 (Takara Bio, Shiga, Japan) as described previously [19]. The sequences used in our
323 study are shown in **Supplementary Table 3**. Quantitative RT-PCR was performed

324 using a SYBR green system on the Applied Biosystem PRISM7700 instrument
325 (Applied Biosystems, Carlsbad, CA), and experiments were conducted using 0.4 μ M
326 of each primer in a final reaction volume of 20 μ l of KAPA SYBR® FAST qPCR kit
327 (Kapa Biosystems, South Africa). The PCR cycling conditions were as follows: 95°C
328 for 30 sec, and 50 cycles of 95°C for 5 sec, 60°C for 1 min. The normalized threshold
329 cycle (Ct) value of each gene was obtained by subtracting the Ct value obtained for
330 18S rRNA. The cardiac mRNA levels were analyzed on POD5. **Figure 4** indicates the
331 number of copies of each of the three representative mRNAs measured in the
332 syngeneic grafts or allografts obtained from three individuals. The relative amount of
333 each mRNA was normalized to that of 18S rRNA. All experiments were analyzed in
334 three mice per each time point and expressed as the mean \pm SEM. * $p < 0.05$ compared
335 with syngeneic on day 5.

336

337 **Acknowledgments/ FUNDING**

338 This study was supported by research grants from National Natural Science
339 Foundation of China (31521003) and the 111 Project (B13016), and the National
340 Center for Child Health and Development (26-6), Ministry of Education, Culture,
341 Sports, Science and Technology of Japan (Grants-in-Aid 15F15756 and 15K10043).

342

343 **Author Contributions**

344 W.Z., Y.W., X.L. and J.W. designed the project. L.S. supported the MAQC data, and
345 M.F. and X.L. supported the mouse model and validations. W.Z. carried out the
346 analysis and simulations. W.Z., X.L. and J.W. wrote the manuscript. L.J., X.L. and
347 J.W. contributed to the final revision the paper. All authors read and approved the final
348 manuscript.

349

350 **References:**

- 351 1. Consortium, M.Shi, L.Reid, L. H.Jones, W. D.Shippy, R.Warrington, J. A.Baker, S. C.Collins, P. J.de
352 Longueville, F.Kawasaki, E. S.Lee, K. Y.Luo, Y.Sun, Y. A.Willey, J. C.Setterquist, R. A.Fischer, G. M.Tong,
353 W.Dragan, Y. P.Dix, D. J.Frueh, F. W.Goodsaid, F. M.Herman, D.Jensen, R. V.Johnson, C. D.Lobenhofer, E.

354 K.Puri, R. K.Schrif, U.Thierry-Mieg, J.Wang, C.Wilson, M.Wolber, P. K.Zhang, L.Amur, S.Bao, W.Barbaciuru,
355 C. C.Lucas, A. B.Bertholet, V.Boysen, C.Bromley, B.Brown, D.Brunner, A.Canales, R.Cao, X. M.Cebula, T.
356 A.Chen, J. J.Cheng, J.Chu, T. M.Chudin, E.Corson, J.Corton, J. C.Croner, L. J.Davies, C.Davison, T.
357 S.Delenstarr, G.Deng, X.Dorris, D.Eklund, A. C.Fan, X. H.Fang, H.Fulmer-Smentek, S.Fuscoe, J.
358 C.Gallagher, K.Ge, W.Guo, L.Guo, X.Hager, J.Haje, P. K.Han, J.Han, T.Harbottle, H. C.Harris, S.
359 C.Hatchwell, E.Hauser, C. A.Hester, S.Hong, H.Hurban, P.Jackson, S. A.Ji, H.Knight, C. R.Kuo, W.
360 P.LeClerc, J. E.Levy, S.Li, Q. Z.Liu, C.Liu, Y.Lombardi, M. J.Ma, Y.Magnuson, S. R.Maqsodi, B.McDaniel,
361 T.Mei, N.Myklebost, O.Ning, B.Novoradovskaya, N.Orr, M. S.Osborn, T. W.Papallo, A.Patterson, T.
362 A.Perkins, R. G.Peters, E. H., et al. (2006) The MicroArray Quality Control (MAQC) project shows inter-
363 and intraplatform reproducibility of gene expression measurements, *Nature biotechnology*. **24**,
364 1151-61.

365 2. Smyth, G. K. (2004) Linear models and empirical bayes methods for assessing differential
366 expression in microarray experiments, *Statistical applications in genetics and molecular biology*. **3**,
367 Article3.

368 3. Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W. & Smyth, G. K. (2015) limma powers
369 differential expression analyses for RNA-sequencing and microarray studies, *Nucleic acids research*. **43**,
370 e47.

371 4. Rice, J. A. (2007) *Mathematical statistics and data analysis*, 3rd edn, Thomson/Brooks/Cole,
372 Belmont, CA.

373 5. Vaux, D. L., Fidler, F. & Cumming, G. (2012) Replicates and repeats--what is the difference and is it
374 significant? A brief discussion of statistics and experimental design, *EMBO reports*. **13**, 291-6.

375 6. Fomel, S. & Claerbout, J. F. (2009) Guest Editors' Introduction: Reproducible Research, *Computing*
376 *in Science & Engineering*. **11**, 5-7.

377 7. Shi, L.Campbell, G.Jones, W. D.Campagne, F.Wen, Z.Walker, S. J.Su, Z.Chu, T. M.Goodsaid, F.
378 M.Pusztai, L.Shaughnessy, J. D., Jr.Oberthuer, A.Thomas, R. S.Paules, R. S.Fielden, M.Barlogie, B.Chen,
379 W.Du, P.Fischer, M.Furlanello, C.Gallas, B. D.Ge, X.Megherbi, D. B.Symmans, W. F.Wang, M. D.Zhang,
380 J.Bitter, H.Brors, B.Bushel, P. R.Bylesjo, M.Chen, M.Cheng, J.Cheng, J.Chou, J.Davison, T. S.Delorenzi,
381 M.Deng, Y.Devanarayan, V.Dix, D. J.Dopazo, J.Dorff, K. C.Elloumi, F.Fan, J.Fan, S.Fan, X.Fang,
382 H.Gonzaludo, N.Hess, K. R.Hong, H.Huan, J.Irizarry, R. A.Judson, R.Juraeva, D.Lababidi, S.Lambert, C.
383 G.Li, L.Li, Y.Li, Z.Lin, S. M.Liu, G.Lobenhofer, E. K.Luo, J.Luo, W.McCall, M. N.Nikolsky, Y.Pennello, G.

- 384 A.Perkins, R. G.Philip, R.Popovici, V.Price, N. D.Qian, F.Scherer, A.Shi, T.Shi, W.Sung, J.Thierry-Mieg,
385 D.Thierry-Mieg, J.Thodima, V.Trygg, J.Vishnuvajjala, L.Wang, S. J.Wu, J.Wu, Y.Xie, Q.Yousef, W. A.Zhang,
386 L.Zhang, X.Zhong, S.Zhou, Y.Zhu, S.Arasappan, D.Bao, W.Lucas, A. B.Berthold, F.Brennan, R. J.Buness,
387 A.Catalano, J. G.Chang, C.Chen, R.Cheng, Y., et al. (2010) The MicroArray Quality Control (MAQC)-II
388 study of common practices for the development and validation of microarray-based predictive models,
389 *Nature biotechnology*. **28**, 827-38.
- 390 8. Barrett, T. & Edgar, R. (2006) Mining microarray data at NCBI's Gene Expression Omnibus (GEO)*,
391 *Methods in molecular biology*. **338**, 175-90.
- 392 9. Roy, N. C., Altermann, E., Park, Z. A. & McNabb, W. C. (2011) A comparison of analog and
393 Next-Generation transcriptomic tools for mammalian studies, *Briefings in functional genomics*. **10**,
394 135-50.
- 395 10. Wang, Y., Li, Y., Cao, H., Xiong, M., Shugart, Y. Y. & Jin, L. (2015) Efficient test for nonlinear
396 dependence of two continuous variables, *BMC bioinformatics*. **16**, 260.
- 397 11. Cui, X. & Churchill, G. A. (2003) Statistical tests for differential expression in cDNA microarray
398 experiments, *Genome biology*. **4**, 210.
- 399 12. Morita, M., Chen, J., Fujino, M., Kitazawa, Y., Sugioka, A., Zhong, L. & Li, X. K. (2014) Identification
400 of microRNAs involved in acute rejection and spontaneous tolerance in murine hepatic allografts,
401 *Scientific reports*. **4**, 6649.
- 402 13. Chen, X., Chang, C. H., Stein, R., Cardillo, T. M., Gold, D. V. & Goldenberg, D. M. (2013) Prevention
403 of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74
404 antagonistic antibody milatuzumab, *Biology of blood and marrow transplantation : journal of the*
405 *American Society for Blood and Marrow Transplantation*. **19**, 28-39.
- 406 14. Fujiwara, H., Maeda, Y., Kobayashi, K., Nishimori, H., Matsuoka, K., Fujii, N., Kondo, E., Tanaka, T.,
407 Chen, L., Azuma, M., Yagita, H. & Tanimoto, M. (2014) Programmed death-1 pathway in host tissues
408 ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease, *Journal of*
409 *immunology*. **193**, 2565-73.
- 410 15. Hou, J., Zhang, Q., Fujino, M., Cai, S., Ito, H., Takahashi, K., Abe, F., Nakajima, M., Tanaka, T., Xu, J.,
411 Zou, H., Ding, Q. & Li, X. K. (2015) 5-Aminolevulinic acid with ferrous iron induces permanent cardiac
412 allograft acceptance in mice via induction of regulatory cells, *The Journal of heart and lung*
413 *transplantation : the official publication of the International Society for Heart Transplantation*. **34**,

414 254-63.

415 16. Wang, Y., Li, Y., Cao, H., Xiong, M., Shugart, Y. Y. & Jin, L. (2015) Efficient test for nonlinear
416 dependence of two continuous variables, *BMC bioinformatics*. **16**, 260.

417 17. Dennis, G., Jr., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C. & Lempicki, R. A. (2003)
418 DAVID: Database for Annotation, Visualization, and Integrated Discovery, *Genome biology*. **4**, P3.

419 18. Edgar, R., Domrachev, M. & Lash, A. E. (2002) Gene Expression Omnibus: NCBI gene expression
420 and hybridization array data repository, *Nucleic acids research*. **30**, 207-10.

421 19. Nishio, Y., Fujino, M., Cai, S., Kitajima, Y., Saito, T., Tsumura, H., Ito, M., Ito, Y., Nagahara, Y. & Li, X.
422 K. (2016) Impaired CD98 signaling protects against graft-versus-host disease by increasing regulatory T
423 cells, *Transplant immunology*. **35**, 34-9.

424

425 **Figure Legends:**

426 Figure 1. *Histograms of False Positive Rate (FPR) and False Negative Rate (FNR)*
427 *from the three methods under the null hypothesis (H0) and the alternative hypothesis*
428 *(H1).*

429 (A) The FPR histogram under the null hypothesis (FN = 0). (B) The histograms under
430 different alternative hypotheses, in which θ is equal to 10%, 25% and 50% and the
431 simulated real positive calls is 1%, 5% and 10% of the whole simulated data,
432 respectively. The significant threshold is 0.05.

433

434 Figure 2. *Heat maps of reproducibility analysis.*

435 (A) The reproducibility of top 100 significant genes by *T-test*, *Limma* and *SFC*,
436 respectively, based on the MAQC data; (B) The reproducibility of top 1000 significant
437 genes by the three methods based on the MAQC data; (C) the reproducibility of
438 significant genes by the three methods based on pairwise analysis of data from the
439 mouse cardiac graft model.

440

441 Figure 3. *Venn diagram of significant genes analyzed by SFC with the significant*
442 *p-value under 0.05 after the Bonferroni correction.*

443 The overall numbers of significant genes in three phases are shown outside, which are

444 followed by numbers in the brackets showing the counts of over-expressed genes
 445 versus under-expressed ones. The circle on the top represents POD5 for heart; the
 446 circle on the left bottom represents POD5 for liver and the one on the right bottom
 447 represents POD8 for liver.

448

449 Figure 4. *Validation of the microarray data using a qRT-PCR assay in the mouse*
 450 *cardiac graft model and hepatic graft model.*

451 (A) The graph shows the cardiac mRNA levels analyzed on POD5, indicating the
 452 values of mRNAs measured in the syngeneic grafts (CONT) or allografts (D5)
 453 obtained from three individuals; (B) The graph shows the hepatic mRNA levels
 454 analyzed on POD5 and POD8, indicating the value of mRNAs measured in the
 455 syngeneic grafts (CONT) or allografts (D5 or D8) obtained from three individuals. A
 456 two-tailed unpaired t-test was used to calculate p-values comparing syngeneic grafts
 457 to allografts.

458

459 **Table 1. Evaluation of three methods with the significant p-value under 0.05.**

| | T-test | Limma | SFC | |
|--|--------|--------|-------|---------------|
| H0 | | | | |
| FPR (%) | 5.043 | 5.222 | 5.694 | |
| FNR (%) | 0.000 | 0.000 | 0.000 | |
| Calls in total (%) | 5.043 | 5.222 | 5.694 | |
| H1 : simulated real positive calls = 1% | | | | |
| | 6.043 | 5.455 | 5.350 | $\theta=10\%$ |
| FPR (%) | 8.763 | 6.306 | 5.038 | $\theta=25\%$ |
| | 14.255 | 8.600 | 3.990 | $\theta=50\%$ |
| | 6.825 | 15.367 | 6.958 | $\theta=10\%$ |
| FNR (%) | 0.783 | 1.933 | 0.058 | $\theta=25\%$ |
| | 0.808 | 0.025 | 0.000 | $\theta=50\%$ |

| | | | | |
|---|--------|---------|--------|-------|
| | 6.908 | 6.240 | 6.220 | 0=10% |
| Calls in total (%) | 9.661 | 7.217 | 5.980 | 0=25% |
| | 15.098 | 9.507 | 4.943 | 0=50% |
| H1 : simulated real positive calls = 5% | | | | |
| | 13.306 | 7.987 | 3.616 | 0=10% |
| FPR (%) | 32.978 | 17.856 | 1.818 | 0=25% |
| | 52.026 | 34.301 | 1.057 | 0=50% |
| | 6.942 | 15.283 | 8.224 | 0=10% |
| FNR (%) | 0.492 | 2.108 | 0.075 | 0=25% |
| | 0.699 | 0.020 | 0.000 | 0=50% |
| | 17.290 | 11.820 | 8.020 | 0=10% |
| Calls in total (%) | 36.301 | 21.854 | 6.714 | 0=25% |
| | 54.388 | 37.5817 | 5.999 | 0=50% |
| H1 : simulated real positive calls = 10% | | | | |
| | 27.850 | 13.782 | 1.615 | 0=10% |
| FPR (%) | 56.305 | 35.345 | 0.626 | 0=25% |
| | 73.170 | 57.081 | 0.266 | 0=50% |
| | 7.282 | 15.334 | 9.830 | 0=10% |
| FNR (%) | 0.551 | 2.042 | 0.277 | 0=25% |
| | 0.652 | 0.019 | 0.000 | 0=50% |
| | 34.336 | 20.870 | 10.470 | 0=10% |
| Calls in total (%) | 60.619 | 41.606 | 10.535 | 0=25% |
| | 75.787 | 61.371 | 10.238 | 0=50% |

460 **Table 2. The list of validated genes.**

| Access No. | Gene | Gene name | Fold-heart | Flod-liverD5 | Fold-liverD8 |
|------------|--------------|------------------------------|------------|--------------|--------------|
| NM_008337 | <i>Iifg</i> | interferon gamma | 1593.863 | 54.675 | 72.591 |
| NM_010259 | <i>Gbp2b</i> | guanylate binding protein 2b | 1263.049 | 12.951 | 18.460 |
| NM_013542 | <i>Gzmb</i> | granzyme B | 185.351 | 147.035 | 114.736 |

| | | | | | |
|--------------|-----------------|--|---------|--------|--------|
| NM_008324 | <i>Ido1</i> | indoleamine 2,3-dioxygenase 1 | 103.729 | 38.474 | 47.050 |
| NM_011073 | <i>Prf1</i> | perforin 1 (pore forming protein) | 99.539 | 38.016 | 37.767 |
| NM_008510 | <i>Xcl1</i> | chemokine (C motif) ligand 1 | 82.096 | 27.777 | 26.918 |
| NM_011579 | <i>Tgtp1</i> | T cell specific GTPase 1 | 76.367 | 33.074 | 59.197 |
| NM_021396 | <i>Pdcd1lg2</i> | programmed cell death 1 ligand 2 | 74.231 | 14.479 | 41.463 |
| NM_001081110 | <i>Cd8a</i> | CD8 antigen, alpha chain | 60.400 | 33.458 | 32.012 |
| NM_024253 | <i>Nkg7</i> | natural killer cell group 7 sequence | 47.828 | 38.247 | 30.322 |
| NM_019465 | <i>Crtam</i> | cytotoxic and regulatory T cell molecule | 46.089 | 26.296 | 15.863 |
| NM_001033126 | <i>Cd27</i> | CD27 antigen | 33.240 | 39.830 | 41.565 |
| NM_008798 | <i>Pdcd1</i> | programmed cell death 1 | 29.391 | 74.356 | 69.542 |
| NM_033078 | <i>Klrk1</i> | killer cell lectin-like receptor subfamily K, member 1 | 28.611 | 18.487 | 16.631 |
| NM_008530 | <i>Ly6f</i> | lymphocyte antigen 6 complex, locus F | 27.006 | 56.930 | 29.637 |
| NM_011612 | <i>Tnfrsf9</i> | tumor necrosis factor receptor superfamily, member 9 | 26.947 | 30.625 | 29.872 |
| NM_009977 | <i>Cst7</i> | cystatin F (leukocystatin) | 25.625 | 26.383 | 30.931 |
| NM_011337 | <i>Ccl3</i> | chemokine (C-C motif) ligand 3 | 21.102 | 47.883 | 82.279 |
| NM_013652 | <i>Ccl4</i> | chemokine (C-C motif) ligand 4 | 19.907 | 35.686 | 56.794 |

461

462 **Supplementary Figure legends**

463 Supplementary Figure 1. *Distribution of mean and variance of sample microarray*
 464 *signals in each probe derived from the MAQC data.*

465 The X-axis is the means of microarray signals derived from the MAQC data and
 466 transformed by \ln . The Y-axis is the \ln values of variance.

467

468 Supplementary Figure 2. *Histograms of False Positive Rate (FPR) and False*
 469 *Negative Rate (FNR) from the three methods under the null hypothesis (H_0) and the*
 470 *alternative hypothesis (H_1) with the significant p-value under 0.01.*

471 (A) The FPR histogram under the null hypothesis ($\theta = 0$). (B) The histograms under
 472 different alternative hypotheses, in which θ is equal to 10%, 25% and 50% and the
 473 simulated real positive calls is 1%, 5% and 10% of the whole simulated data,

474 respectively.

475

476 Supplementary Figure 3. *Histograms of False Positive Rate (FPR) and False*
477 *Negative Rate (FNR) from the three methods under the null hypothesis (H0) and the*
478 *alternative hypothesis (H1) with the significant p-value under 0.001.*

479 (A) The FPR histogram under the null hypothesis (FN = 0). (B) The histograms under
480 different alternative hypotheses, in which θ is equal to 10%, 25% and 50% and the
481 simulated real positive calls is 1%, 5% and 10% of the whole simulated data,
482 respectively.

483

484 Supplementary Figure 4. *Venn diagrams of significant gene numbers analyzed by*
485 *T-test and Limma with the significant p-value under 0.05 after the Bonferroni*
486 *correction.*

487 The numbers of significant genes in three phases are shown outside, which are
488 followed by numbers in the brackets showing the counts of over-expressed genes
489 versus under-expressed ones. The circle on the top represents POD5 for heart; the
490 circle on the left bottom represents POD5 for liver and the one on the right bottom
491 represents POD8 for liver.

492

493 Supplementary Figure 5. *Venn diagrams of significant gene numbers analyzed by*
494 *T-test, Limma and SFC with the significant p-value under 0.05.*

495 The numbers of significant genes in three phases are shown outside, which are
496 followed by numbers in the brackets showing the counts of over-expressed genes
497 versus under-expressed ones. The circle on the top represents POD5 for heart; the
498 circle on the left bottom represents POD5 for liver and the one on the right bottom
499 represents POD8 for liver. Every part of the Venn also display a counting number.

500

501 Supplementary Figure 6. *Venn diagrams of significant gene numbers analyzed by*
502 *T-test, Limma and SFC with the significant p-value under 0.001.*

503 The numbers of significant genes in three phases are shown outside, which are

504 followed by numbers in the brackets showing the counts of over-expressed genes
505 versus under-expressed ones. The circle on the top represents POD5 for heart; the
506 circle on the left bottom represents POD5 for liver and the one on the right bottom
507 represents POD8 for liver. Every part of the Venn also display a counting number.

508

509 **Supplementary Tables**



510 Supplementary Table 1. Evaluation of three methods with the significant p-value
511 under 0.01.

512 Supplementary Table 2. Evaluation of three methods with the significant p-value
513 under 0.001.


514 Supplementary Table 3. Primer sequences for qRT-PCR.

515 Supplementary Table 4. GO term and pathway enrichment analysis based on the 52
516 significant genes. Sheet 1: GO term enrichment analysis with three categories BP
517 (biological process), MF (molecular function) and CC (cellular component).


518 Sheet 2: Pathway enrichment analysis based on the KEGG dataset.





feb4_12343_f1.tiff



feb4_12343_f2.tiff





feb4_12343_f4.tiff